Press Release

Cendifensine demonstrates 92% reduction in number of hot flashes Basel, Switzerland and Boston, MA – November 6, 2025 – Noema Pharma AG today announced positive topline results from a Phase 2a, open-label study evaluating cendifensine in menopausal women experiencing moderate-to-severe vasomotor symptoms (VMS), including hot flashes and night sweats. The results suggest that cendifensine may […]

Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development BASEL, Switzerland, January 8, 2025 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Michael Samar as Chief Financial Officer. “We are thrilled to

BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of Volker Knappertz, M.D., as Executive Vice President of Research & Development. “We are excited to welcome Volker to Noema. Volker is a recognized leader in drug development with a

Basel, Switzerland, December 11, 2024 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 million (approx. USD 147 million). With its

– Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome – BASEL, Switzerland, Oct. 30, 2024 – Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study evaluating the safety and efficacy of gemlapodect (NOE-105) in Tourette syndrome.

– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients completing the study at the target clinical dose range were responders based on the primary efficacy assessment The Yale Global Tics Severity Scale Total Tic Score (YGTSS-TTS) showed a statistically significant improvement of -7.8 points

Top-line results from Phase 2B study expected in first quarter of 2025 BASEL, Switzerland, August 13, 2024 – Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders with first-in-disease therapeutic approaches, today announced the completion of enrollment in the GALENE Phase 2B trial, a double-blind, placebo-controlled trial evaluating the efficacy of NOE-101 for seizure

NOE-115 has the potential to benefit Vasomotor Symptoms (VMS) during menopause as well as associated clinical challenges including weight gain, daytime fatigue, and cognitive symptoms BASEL, Switzerland, May 22, 2024 – Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders, today announced the first patient has been dosed in a Phase 2a open-label

BASEL, Switzerland, January 3, 2024 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of management will attend and present at two upcoming conferences in San Francisco, CA. SACHS 7th Annual Neuroscience Innovation ForumFormat: Panel Discussion Title: Exploring New Modalities for Rare & Orphan Neurological Diseases

— Appointment supports Noema’s robust clinical-stage pipeline addressing high value CNS disorders — BASEL, Switzerland, November 15, 2023 — Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser, M.D., M.B.A has joined the Company as Chief Medical Officer (CMO). “Dr. Lasser brings over 25 years of CNS